Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of IVT Shigella-04 in Healthy Young Adults
NCT07205926Phase 1Recruiting
- Sponsor
- Inventprise
- Start
- Oct 2025
- Primary completion
- Jan 2026
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IVT Shigella-04 in shigellosis (6 arms), sponsored by Inventprise. Primary endpoints: Percentage of participants with reactogenicity events, Percentage of participants with adverse events (AEs) and 3 more. Started Oct 2025; status: recruiting.
02
Drugs
IVT Shigella-04
03
Conditions
shigellosis
Beyond the preview
Go deeper on NCT07205926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07205926.